S. Tamir Rashid, Graeme J.M. Alexander  Journal of Hepatology 

Slides:



Advertisements
Similar presentations
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Ann Intern Med. 2011;155(2): doi: / Figure Legend:
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Inflammasomes in liver diseases
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Pluripotent stem cell based gene therapy for hematological diseases
Stem cell therapeutic possibilities: future therapeutic options for male-factor and female- factor infertility?  Charles A. Easley, Calvin R. Simerly,
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Functional neutrophils from human ES cells
Use of Induced Pluripotent Stem Cells in Dermatological Research
The 3D Genome Shapes Up For Pluripotency
Pluripotent Stem Cells from Cloned Human Embryos: Success at Long Last
Immigration and viral hepatitis
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Living donor liver transplantation: is the hype over?
K. L. Nash, M. E. Allison, D. McKeon, D. J. Lomas, C. S. Haworth, D
European Association for the Study of the Liver  Journal of Hepatology 
David G. Zacharias, BA, Timothy J. Nelson, MD, PhD, Paul S
Mesenchymal stromal cell therapy for liver diseases
Reply to: “DCD consensus and futility in liver transplantation”
Advances in basic and clinical immunology in 2011
Robert Zweigerdt, Ina Gruh, Ulrich Martin  Cell Stem Cell 
Nat. Rev. Cardiol. doi: /nrcardio
Hepatitis C core protein – The “core” of immune deception?
Volume 61, Issue 1, Pages S108-S119 (November 2014)
Recreating Pluripotency?
Etienne C. E. Wang, MBBS, PhD, Zhenpeng Dai, PhD, Angela M
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Volume 70, Issue 1, Pages (January 2019)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Aloysious D. Aravinthan, Graeme J.M. Alexander  Journal of Hepatology 
Nat. Rev. Nephrol. doi: /nrneph
Volume 62, Issue 3, Pages (March 2015)
Liver is liver and blood is blood, and finally the twain have met
Loukia Yiangou, Alexander D.B. Ross, Kim Jee Goh, Ludovic Vallier 
Genomic risk of hepatitis C-related hepatocellular carcinoma
A rapidly evolving revolution in stem cell biology and medicine
Pluripotent Stem Cells and Disease Modeling
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Induced pluripotent stem cells: A new era for hepatology
The changing role of beta-blocker therapy in patients with cirrhosis
Volume 21, Issue 1, Pages (July 2017)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Clinical Practice Guidelines of the European Association for the study of the Liver – Advancing methodology but preserving practicability  Markus Cornberg,
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 63, Issue 1, Pages (July 2015)
The use of hemospray in portal hypertensive bleeding; a case series
Volume 62, Issue 3, Pages (March 2015)
A Fresh Look at iPS Cells
HCV animal models and liver disease
Liver transplantation in children
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Pathogenesis of cholestatic hepatitis C
Embryonic and adult stem cell therapy
Roberto Ensenat-Waser, Ph. D. , Antonio Pellicer, M. D. , Ph. D
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Cellular Alchemy and the Golden Age of Reprogramming
Modeling Brain Disease in a Dish: Really?
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Induced pluripotent stem cells: From Nobel Prizes to clinical applications  S. Tamir Rashid, Graeme J.M. Alexander  Journal of Hepatology  Volume 58, Issue 3, Pages 625-629 (March 2013) DOI: 10.1016/j.jhep.2012.10.026 Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Derivation of pluripotent stem cells. Pluripotent stem cells, possessing the ability to form any cell type of the human body, can be created using in vitro fertilisation (Steptoe and Edwards), somatic cell nuclear transfer (Gurdon), and transcription factor overexpression (Yamanaka). Journal of Hepatology 2013 58, 625-629DOI: (10.1016/j.jhep.2012.10.026) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Using iPSCs for human therapy. Patient specific skin samples are firstly reprogrammed into iPSCs. Genetic diseases could then be treated by editing the genomes of iPSCS, differentiating them into target adult cells, and finally transplanting the corrected cells back into the original patient. Journal of Hepatology 2013 58, 625-629DOI: (10.1016/j.jhep.2012.10.026) Copyright © 2012 European Association for the Study of the Liver Terms and Conditions